 I. To determine the safe dose of olaparib with ramucirumab, but not to exceed olaparib dose of 300 mg twice daily tablet formulation. Phase I II. To determine the efficacy of olaparib plus ramucirumab as measured by the objective response rate ORR. Phase II. 